Drug Patents owned by Clivunel Inc
1. List of Scenesse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076555 | CLIVUNEL INC | Methods of inducing melanogenesis in a subject |
Feb, 2025
(1 year, 8 months from now) | |
| US8334265 | CLIVUNEL INC | Method of treatment of photodermatoses |
Mar, 2029
(5 years from now) | |
Do you want to check out SCENESSE patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 8, 2026 |
| New Chemical Entity Exclusivity (NCE) | Oct 8, 2024 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 2023-10-09
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT;SUBCUTANEOUS
More Information on Dosage
SCENESSE family patents
6
Australia
6
United States
3
Slovenia
3
Denmark
3
Spain
3
European Union
2
Canada
2
New Zealand
2
Portugal
2
Hungary
2
Poland
1
Netherlands
1
Cyprus
1
China
1
South Africa
1
Luxembourg
1
Japan
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic